Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Sarepta Therapeutics has shared an update about themulti-ascending dose clinical trial of SRP-5051 for patients with Duchennemuscular dystrophy who are amenable to exon 51 skipping.
They have reported strong, dose-dependent exon-skipping anddystrophin expression results with monthly dosing of SRP-5051 in ambulant andnon-ambulant patients.